普罗格拉努林通过GSK3β信号传递,防止高血糖引起的神经功能障碍
Cass Dedert1,2, Lyuba Salih1,2, Fenglian Xu1,2,3,4
1Department of Biology, College of Arts and Sciences, Saint Louis University, Saint Louis, MO 63103, USA.
Cells
|July 14, 2023
概括
益格拉努林通过涉及糖原合成酶激酶3β (GSK3β) 来保护神经元免受高血糖的影响. 这一发现为治疗糖尿病神经损伤提供了新的途径.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 内分泌学 在内分泌学.
背景情况:
- 二型糖尿病影响全球超过5.3亿人,往往导致神经问题.
- 高血糖是糖尿病病理学的关键驱动因素,使得葡萄糖调节至关重要.
- 神经元生长因子progranulin显示出对高血糖压力的潜在神经保护作用.
研究的目的:
- 为了调查糖原合成酶激酶3β (GSK3β) 在progranulin神经保护作用中的作用.
- 评估progranulin和GSK3β抑制如何影响高葡萄糖条件下的神经元健康和功能.
- 探索受益于progranulin和GSK3β的下游信号通路.
主要方法:
- 主要小鼠皮层神经元被暴露在高葡萄糖条件下.
- 神经元用progranulin和选择性GSK3β抑制剂进行治疗.
- 评估了神经元活力,自流 (LC3B,LAMP2A),信号和神经元发射.
主要成果:
- 在高血糖症下,progranulin以GSK3β依赖的方式改善了全细胞和线粒体活力.
- 自流量标记物显示出与前列蛋白和GSK3β抑制的复杂变化.
- 抑制GSK3β调节的信号传递和神经元发射受progranulin的影响.
结论:
- GSK3β对于前列腺素对抗高血糖压力的神经保护作用至关重要.
- 这些发现突出了GSK3β作为糖尿病神经病变的潜在治疗点.
- 益格拉努林的保护机制需要在神经退行性疾病模型中进行进一步的研究.
更多相关视频
07:58Establishment of a Surgically-induced Model in Mice to Investigate the Protective Role of Progranulin in Osteoarthritis
Published on: February 25, 2014
28.6K
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
9.8K
相关概念视频
Hypoglycemia and Glucagon
305
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
305
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189
Glucagon-like Receptor Agonists
364
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
364
